Abstract:

Objective To investigate the clinical effect of  docetaxel combined with oxaliplatin in advanced nonsmall cell lung cancer. Methods  A total of 118 patients with advanced nonsmallcell lung cancer  were randomly divided into observation group and control group， 59 cases in each group. The control group was treated with cisplatin combined with docetaxel and the observation group was treated with oxaliplatin combined with docetaxel. The differences of solid tumor efficacy， time to progression， overall survival time， and adverse reaction rate of patients in both groups were compared. Results  The rates of complete remission， partial remission and clinical effect in observation group were 11.9% (7/59)， 47.5% (28/59) and 59.3% (35/59)， respectively， which were higher than 8.5% (5/59)，39.0% (23/59) and 47.5% (28/59) in control group， respectively (P>0.05). The time to progression and overall survival time in observation group were (12.17±0.98)  months and  (20.07±2.38)  months， respectively， which were significantly higher than (8.48±0.68) months and (16.07±2.78) months in control group， respectively (P<0.05). The rates of bone marrow depression， digestive tract abnormalities， decreased white blood cells， peripheral nerve toxicity， liver function abnormalities and other adverse reactions were significantly lower in observation group than in control group， and the degree was significantly improved in control group (P<0.05).Conclusion  Docetaxel combined with oxaliplatin has an affirmative clinical efficacy in advanced nonsmall cell lung cancer with lower adverse reactions and is one of the effective measures in the treatment of advanced nonsmall cell lung cancer.

Key words: carcinoma, nonsmallcell lung, antineoplastic combined chemotherapy protocols, docetaxel, cisplatin